Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial. - Yen CJ; Chen MH; Chen YY; Bai LY; Chen JS; Hsieh JC; Shih YH; Wu IC; Chen YL; Chen CM; Chao TY; Chu YW; et al. (British journal of cancer, 2026)